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Apparently Normal Ovarian Differentiation in a Prepubertal Girl
with Transcriptionally Inactive Steroidogenic Factor 1 (NR5A1/SF-1)
and Adrenocortical Insufficiency
Anna Biason-Lauber1,2 and Eugen J. Schoenle1
Departments of 1Endocrinology and Diabetology and 2Clinical Chemistry and Biochemistry, University Children’s Hospital, Zurich
Steroidogenic factor 1 (NR5A1/SF-1) plays an essential role in the development of the hypothalamic-pituitary-
adrenal and hypothalamic-pituitary-gonadal axes, controlling expression of their many important genes. The recent
description of a 46,XY patient bearing a mutation in the NR5A1 gene, causing male pseudohermaphroditism and
adrenal failure, demonstrated the crucial role of SF-1 in male gonadal differentiation. The role of SF-1 in human
ovarian development was, until now, unknown. We describe a phenotypically and genotypically normal girl, with
signs and symptoms of adrenal insufficiency and no apparent defect in ovarian maturation, bearing a heterozygote
GrT transversion in exon 4 of the NR5A1 gene that leads to the missense R255L in the SF-1 protein. The exchange
does not interfere with protein translation and stability. Consistent with the clinical picture, R255L is transcrip-
tionally inactive and has no dominant-negative activity. The inability of the mutant (MUT) NR5A1/SF-1 to bind
canonical DNA sequences might offer a possible explanation for the failure of the mutant protein to transactivate
target genes. This is the first report of a mutation in the NR5A1 gene in a genotypically female patient, and it
suggests that NR5A1/SF-1 is not necessary for female gonadal development, confirming the crucial role of NR5A1/
SF-1 in adrenal gland formation in both sexes.
Steroidogenic factor 1 (SF-1), an orphan nuclear receptor
alternatively designated “adrenal 4-binding protein,”
now known as “nuclear receptor subfamily 5 group A
member 1” (NR5A1 [MIM 184757]), was initially de-
scribed as an important regulator of the tissue-specific
expression of the cytochrome P450 steroid hydroxylases
(Lala et al. 1992), 3-@b-hydroxysteroid dehydrogenase
deficiency (MIM 201810), and steroidogenic acute re-
sponse protein (STAR [MIM 600617]). Analyses of Ftz-
F1 knockout mice showed that Sf-1 is essential for nor-
mal development of the adrenals and gonads (Luo et al.
1994). Since its characterization, several lines of research
have demonstrated that SF-1 regulates the expression of
both classes of hormones essential for male phenotypic
differentiation—androgens and anti-Mu¨llerian hormone
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(AMH [MIM 600957]). Apart from the adrenal gland
and hypothalamus, Sf-1 is expressed in both male and
female mouse embryos from very early stages of gona-
dogenesis, when the mesoderm condenses to form the
urogenital ridge. With the onset of testicular differentia-
tion, the levels of Ftz-F1 transcripts increase in both func-
tional compartments of the testes—the interstitial region
(androgen-producing Leydig cells) and the testicular cords
(AMH-producing Sertoli cells). In contrast, Ftz-F1 tran-
scripts in ovaries decrease in coincidence with sexual dif-
ferentiation, suggesting that the persistent expression of
Sf-1 may inhibit female sexual differentiation.
To examine the role of the gene in intact mice, Luo
et al. (1994) used targeted disruption of the Ftz-F1 gene.
Despite normal survival in utero, all Ftz-F1 null animals
died by postnatal day 8; these animals lacked adrenal
glands and gonads and were severely deficient in corti-
costerone, supporting adrenocortical insufficiency as the
probable cause of death. Male and female Ftz-F1 null
mice had female internal genitalia, despite complete go-
nadal agenesis. These studies established that the Ftz-F1
gene is essential for sexual differentiation and for for-
mation of the primary steroidogenic tissues.
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Figure 1 NR5A1 gene (a) and protein (b). Blackened boxes represent the coding exons; unblackened boxes, the noncoding exons. The
sizes (in base pairs) of the PCR products are also indicated. The oligonucleotides used for genomic DNA amplification are depicted by arrows.
The position of the transversion in exon 4 and the correspondent R255L missense mutation in the hinge region of the NR5A1/SF-1 protein
are sketched. P box p proximal box; D box p distal box; A box p FTZ-F1 box; PRR p proline-rich region; regions II and III p domains
conserved among NR5A1/SF-1 proteins with unclear function; AF-2p activation function domain. c, DNA sequences. Chromatograms obtained
by direct sequencing of PCR products showing the presence of the heterozygote GrT substitution in exon 4, not present in healthy individuals
(WT, representative example from 30, 60 alleles). d, Restriction endonuclease analysis of a 626-bp exon 4 PCR product. The rearrangement
introduces a novel MnlI (CCTC[N]7) restriction site that generates two additional bands of 27 and 70 bp in the patient, leaving another 90-
bp band intact. The presence of the transversion in the heterozygote state was confirmed by restriction analysis in cloned and amplified DNA.
In humans, the importance of NR5A1/SF-1 in male
gonadal differentiation has been confirmed by the de-
scription of a 46,XY patient affected by adrenal insuf-
ficiency and male pseudohermaphroditism (Achermann
et al. 1999). Since no mutation was described in 46,XX
patients, the role of NR5A1/SF-1 in human ovarian de-
velopment was, until now, not known. In this report,
we describe the first example of a female patient deficient
in NR5A1/SF-1.
A phenotypically normal girl presented at age 14 mo
with adrenal insufficiency and seizures after having had
otitis and tonsillitis 1 wk earlier. The diagnosis of ad-
renocortical insufficiency was based on the clinical pic-
ture of severe slackness, muscular hypotonia, and the
typical laboratory results of decreased sodium (104
mmol/liter; normal range 135–145), increased potas-
sium (8.0 mmol/liter; normal range 3.5–4.8), elevated
ACTH (2200 pg/ml; normal range 10–50 pg/ml), and
inadequately low cortisol in plasma (165 nmol/liter) and
urine (free urinary cortisol, 17.6 mg/m2/24 h; normal
values 20–100 mg/m2/24 h) cortisol. All urinary steroid
hormone metabolites were undetectable, excluding con-
genital adrenal hyperplasia caused by an enzyme defect
of the steroid hormone pathway. Because cholesterol was
absent in the urine, a diagnosis of STAR deficiency was
unlikely. The personal history of the first year of life of
the girl was uneventful, as was the family history with
respect to adrenal insufficiency.
Under treatment with hydrocortisone (7.5 mg/d) and
fludrocortisone (0.1 mg/d), the clinical signs normalized
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Figure 2 Expression of WT and MUT NR5A1/SF-1. Western
blot analysis was performed on protein extract of 293 cells transiently
transfected with an empty pCMV4 vector (), the expression vector
containing the WT NR5A1/SF-1 cDNA or the MUT NR5A1/SF-1
R255L cDNA, using lipofectamine reagent (Life Technologies). As pos-
itive control, protein extract from NCI-H295R human adrenal car-
cinoma cells was used (H295R). The antihuman NR5A1/SF-1 anti-
bodies were used at 1:250 dilution and were purchased from Upstate
Biotechnology. The R255L rearrangement does not interfere with pro-
tein translation or stability.
Figure 3 a, DNA-binding capacity of human MUT NR5A1/SF-
1. Nuclear extracts prepared from 293 cells transfected with WT in
the absence or presence of a 10-fold excess cold competitor (WT 
c) or MUT NR5A1/SF-1 underwent electrophoretic mobility-shift as-
say using phospholabeled probes corresponding to one of the two sites
of the human CYP11A promoter (110 to 49). Similar results were
obtained by use of the other binding site (1679/1620) (not shown).
A non-NR5A1/SF-1 protein binding to the110/49 sequence is also
present in the reaction (?). b, Western blot analysis demonstrating that
the differences in binding capacity are not due to variations in ex-
pression between WT and MUT NR5A1/SF-1. The protein extract
duplicates were loaded in two different amounts (100 and 50 mg).
within 2 d. At age 27 mo, growth and psychomotoric
development were completely normal. Additional eval-
uation showed a normal female chromosomal pattern
(46,XX) and normal LH and FSH serum levels (e.g., 0.5
and 2.8 U/liter, respectively) at ages 14 and 27 mo. Pelvic
ultrasonography, besides failing to reveal the adrenals,
showed a normal infantile uterus (2.6 cm) and infantile
ovaries of normal size and structure (maximal diameter
1.2 cm). Magnetic resonance imaging (MRI) also con-
firmed the presence of ovaries normal in location. To
further characterize the function of the ovaries, we per-
formed inhibin A and B assays (Oxford Bio-innovation).
The inhibin levels were low but normal for age (inhibin
A: 3,1 pg/ml; inhibin B: 4.5 pg/ml) (Sehested et al. 2000)
Therefore, there is no evidence of any abnormality of
the reproductive system. Direct sequencing of PCR frag-
ments amplified from genomic DNA of the patient re-
vealed the presence of a heterozygote GrT transversion
in exon 4 of the NR5A1 gene, leading to the missense
R255L in the hinge region of NR5A1/SF-1 protein (fig.
1a–c). To search for evidence of mosaicism, we obtained
genomic DNA from hair roots (Dracopoli et al. 2000).
The results of mutational analysis of this DNA were
identical to those in leukocytes. Although we cannot ex-
clude that another rearrangement is present in a differ-
ent region of the gene, no mutation was found in the
other exons, in the intron-exon boundaries, or in 500
bp upstream of the start site of transcription. Although
not located in one of the conserved regions, arginine 255
is conserved in the human (National Center for Bio-
technology Information accession number NP004950),
bovine (National Center for Biotechnology Informa-
tion accession number AAB23574), rat (National Cen-
ter for Biotechnology Information accession number
BAA07722]), and mouse (National Center for Biotech-
nology Information accession number S65876) NR5A1/
SF-1 proteins. The rearrangement introduces a novelMnlI
restriction site that is absent in the parents of the patient
(fig. 1d) and in 30 normal controls (60 alleles, not shown)
and, therefore, represents a de novo phenomenon. Since
de novo mutations (germline or somatic) represent a rare
event, we had to confirm parentage via amplification of
microsatellites (D9S1798, D9S1821, and D9S159 [Ge´-
ne´thon] [Dib et al. 1996], not shown). The absence of
pathognomonic cholesterol metabolites in urine and the
lack of rearrangements in STAR cDNA (performed as
described in the study by Biason-Lauber et al. [2000];
National Center for Biotechnology Information accession
number NM000349) allowed us to exclude lipoid adrenal
hyperplasia (not shown).
The mutation in the NR5A1 gene of our patient was
recreated by site-directed mutagenesis and was used for
functional studies in 293 human embryonic kidney cells.
This rearrangement does not interfere with protein trans-
lation and stability, as demonstrated by the western blot
analysis (fig. 2). The MUT NR5A1/SF-1 does not bind
properly to the known responsive element of the human
CYP11A promoter (110/49 [Monte´ et al. 1998]; fig.
3) (MIM 118485 [National Center for Biotechnology In-
formation accession number M604212]). Consistent with
Figure 4 Transcriptional activity of MUT NR5A1/SF-1. A luciferase reporter construct (10 mg) containing two human CYP11A promoter
regions (a and b, blackened bars; binding site 2: 110 to 49; with or without SV40 promoter) and part of the rat Cyp11a promoter region
(c, hatched bars; 81/42) was transfected into 293 cells with WT, MUT NR5A1/SF-1, or a combination of the two (molar ratio 1:1). Mock
transfected 293 cells serve as negative control, whereas the luciferase-containing empty vector (pGL3; Promega) represents background luciferase
activity. The results were subjected to statistical analysis (t-test, paired). *** p ; ** p ; ns p not significant. The dataP ! .0001 P ! .001
represent the mean  SD of three independent experiments.
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the clinical picture, the R255L NR5A1/SF-1 mutant does
not transactivate two known responsive sequences (hu-
man CYP11A promoter, binding site 1:1679 to1620
not shown; binding site 2: 110 to 49; fig. 4a and b)
cloned upstream from a luciferase reporter gene. Similar
results were obtained by means of another target pro-
moter—that is, the rat Cyp11a promoter (National Cen-
ter for Biotechnology Information accession number
J005511),81/42 [Clemens et al. 1994]); (fig. 4c). The
MUT NR5A1 does not show any dominant-negative ac-
tivity when transiently coexpressed with wild-type (WT)
protein (fig. 4). To establish whether the MUT NR5A1/
SF-1 has the same differential activity in adrenal and ovar-
ian cells in vitro as appears to be the case in vivo in our
patient, we performed similar functional studies in human
adrenal adenocarcinoma cells NCI-H295R and ovarian
NIH-OvCar3 cells. Transfection of different amounts (1,
3, and 10 mg) of empty vector—WT and MUT NR5A1/
SF-1 or a combination of the two—did not overcome the
endogenous expression of NR5A1, preventing us from
finding differences in transactivation of the reporter (not
shown).
The recent description of a 46,XY patient bearing a
mutation in the NR5A1 gene causing male pseudoher-
maphroditism and adrenal failure demonstrated the cru-
cial role of SF-1 in male gonadal differentiation (Ach-
ermann et al. 1999). The MUT R255L NR5A1/SF-1 is
unable to properly bind DNA, thus explaining the loss
of transactivation potential of the R255L protein. The
reason for this impaired DNA binding is at present un-
clear, since the mutation is not located in the classic Zn-
fingers or in the A domain, and further experiments are
necessary to clarify this point. The transcriptionally in-
active MUT NR5A1/SF-1 has no dominant-negative ac-
tivity when transiently coexpressed with WT protein. It
is possible that the mutant protein fails to interact with
other proteins involved in adrenal development, such as,
for example, DAX-1 (MIM 300200).
There are several lines of evidence for the interaction
of DAX-1 and NR5A1/SF-1 (for review, see Parker et al.
1999). The consequences of this putative interaction ap-
pear to be tissue dependent. In the adrenal cortex,
NR5A1/SF-1 and DAX-1 may cooperate to activate the
expression of target genes necessary for tissue-specific de-
velopment and functions. The dependence of adrenal de-
velopment and function on NR5A1/SF-1 is confirmed by
the congenital adrenal insufficiency in our patient. In con-
trast, the action of NR5A1/SF-1 (and DAX-1) in gonadal
cells seems to be antithetic. NR5A1/SF-1 is required for
testes development and male sexual differentiation, as
demonstrated by the Ftz-F1 knockout mouse model and
the recent description of a 46,XY phenotypically female
NR5A1/SF-1–deficient patient (Achermann et al. 1999).
On the other hand, the expression of NR5A1/SF-1 in the
ovaries is maintained up to the 15th wk of gestation (Han-
ley et al. 1999) and declines afterwards, at the beginning
of embryonic female sexual differentiation. These findings
suggested that NR5A1/SF-1 is essential for normal male
gonadal differentiation but may not be crucial for, or even
impair, ovarian development. This is consistent with the
clinical presentation of our 46,XX NR5A1/SF-1 mutant
patient who, although still prepubertal, showed no mor-
phological or functional sign of ovarian failure, such as
elevated gonadotropins, which occur, for example, in the
case of prepubertal girls with Turner syndrome. It must
be mentioned, however, that the NR5A1/SF-1 mutation
might affect GnRH and/or FSH-LH release and, therefore,
produce the same effect. It remains to be established
whether NR5A1/SF-1 is necessary for the normal pubertal
maturation of the ovaries. The haploinsufficiency of the
two human patients deficient in NR5A1/SF-1 (Acher-
mann et al. 1999 and the present report), in contrast with
the Ftz-F1 knockout mouse model, could be due to the
fact that the normal allele is not expressed at all. This is
difficult to demonstrate, because, for ethical reasons, it is
not possible to obtain NR5A1/SF-1–expressing tissues
from this patient. For the same reasons, we cannot fully
characterize a putative genetic mosaicism and the stage
of embryonic development in which the de novo mutation
arose. The presence of the mutation in the heterozygote
state in tissues of different embryonic origin (leukocytes
and hair roots) might suggest that the de novo event oc-
curred before the germ layers separate at gastrulation,
implying an ovarian involvement. On the other hand, it
is appealing to hypothesize that NR5A1 represents a fur-
ther example of a dosage-sensitive mechanism of sex dif-
ferentiation in human males, similar to those already
shown for DAX-1, WT1, and SOX9. Perhaps more sig-
nificantly, our results demonstrate that NR5A1, analo-
gous to DAX-1, is not an ovary-determining gene in hu-
mans; the results also indicate the necessity of further
studies in the search for genes responsible for ovarian
determination and differentiation. Our findings provide
insights into the role of NR5A1/SF-1 human ovarian de-
velopment and suggest that NR5A1/SF-1 mutations might
be the molecular basis of non–X-linked congenital adrenal
insufficiency.
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